Skip to main content
Michael Saag, MD, Infectious Disease, Birmingham, AL, Birmingham VA Medical Center

MichaelSSaagMD

Infectious Disease Birmingham, AL

HIV/AIDS Medicine

Professor of Medicine, University Alabama

Dr. Saag is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Saag's full profile

Already have an account?

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Infectious Disease, 1985 - 1987
  • University of Alabama Medical Center
    University of Alabama Medical CenterResidency, Internal Medicine, 1981 - 1984
  • University of Louisville School of Medicine
    University of Louisville School of MedicineClass of 1981

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 1982 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • Elected Member The American Society for Clinical Investigation, 1997
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Misguided Use of Hydroxychloroquine for COVID-19  
    Michael Saag, MD, JAMA
  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults  
    Michael S Saag, Melanie A Thompson, Constance A Benson, Susan P Buchbinder, Joseph J Eron, Donna M Jacobsen, JAMA
  • Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men Who Have Sex with Men and Men Who Have Sex with Women Engaged in Routine HIV Care in the United S...  
    Heidi E Hutton, Karen L Cropsey, Katerina Christopoulos, W Christopher Mathews, Geetanjali Chander, Michael Saag, Heidi M Crane, AIDS and Behavior
  • Join now to see all

Lectures

  • Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment—Reply 
    University of Alabama at Birmingham, Birmingham, AL - 5/15/2014

Press Mentions

  • HIV and Opioid Use Disorder: Screening Tools, Chronic Pain Management, and Access to Care in the Outpatient Setting
    HIV and Opioid Use Disorder: Screening Tools, Chronic Pain Management, and Access to Care in the Outpatient SettingMay 10th, 2023
  • The COVID Vaccine Success Story as a Springboard for Future Research
    The COVID Vaccine Success Story as a Springboard for Future ResearchJanuary 24th, 2023
  • Local Health Officials Plan to Increase Monkeypox Vaccinations
    Local Health Officials Plan to Increase Monkeypox VaccinationsAugust 12th, 2022
  • Join now to see all

Grant Support

  • Alabama-Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
  • Integration Of Evidence-Based Alcohol Interventions Into HIV CareNational Institute On Alcohol Abuse And Alcoholism2011
  • Recent Advances In AIDS And HIV ResearchNational Institute Of Allergy And Infectious Diseases2009–2011
  • Administrative CoreNational Institute Of Allergy And Infectious Diseases2009–2011
  • Unsolicited R24 For The Cfar-Network Of Integrated Clinical Sciences, CnicsNational Institute Of Allergy And Infectious Diseases2006–2011
  • UAB Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2004–2011
  • AdministrativeNational Institute Of Allergy And Infectious Diseases2008
  • ACTG A5229National Center For Research Resources2007
  • ACTG A5209 Ezetimibe (ZETIA) In Combination With Statin Therapy For The TreatmenNational Center For Research Resources2006–2007
  • ACTG A5001 (V 30)National Center For Research Resources2006–2007
  • A5202, Final Version 10, 05/05/05: Initial Therapy With Different AntiretroviraNational Center For Research Resources2006–2007
  • Silcaat V 40National Center For Research Resources2005–2007
  • FRAM 2National Center For Research Resources2005–2007
  • Amd11070 In Hiv-Positive Subjects (A5210)National Center For Research Resources2005–2007
  • ACTG A5146National Center For Research Resources2005–2007
  • ACTG A5068National Center For Research Resources2004–2007
  • Recent Advances In AIDS And HIV ResearchNational Institute Of Allergy And Infectious Diseases2003–2007
  • Adult AIDS Clinical Trials GroupNational Institute Of Allergy And Infectious Diseases2000–2007
  • ACTG A5142, V 20National Center For Research Resources2006
  • ACTG A5186National Center For Research Resources2005–2006
  • ACTG A5178 (Slam-C)National Center For Research Resources2005–2006
  • ACTG A5174 Improving Immune Reconstitution With Growth Hormone In Hiv-InfectedNational Center For Research Resources2005
  • ACTG A5142, V 20 Comparison Of Lopinavir/Ritonavir PLUS Efavirenz VS Lopinavir/National Center For Research Resources2005
  • ACTG A5001 (V 20) Adult AIDS Clinical Trials Group Longitudinal Linked RandomizNational Center For Research Resources2005
  • ACTG 5095 Comparison Of Three Protease Inhibitor-Sparing Regimens For The InitiaNational Center For Research Resources2005
  • ACTG A5181National Center For Research Resources2004–2005
  • Improving Immune Reconstitution With Growth HormoneNational Center For Research Resources2004
  • Comparison Of Lopinavir/Ritonavir PLUS EfavirenzNational Center For Research Resources2004
  • Adult AIDS Clinical Trials Group Longitudinal LinkedNational Center For Research Resources2004
  • ACTG 5095 Comparison Of Three Protease InhibitorNational Center For Research Resources2004
  • Core--ClinicalNational Institute Of Allergy And Infectious Diseases1998–2002
  • Viral/Lymphocyte Dynamics In HIV-1 Infected PatientsNational Center For Research Resources2000
  • T20 Administered To HIV1 Positive AdultsNational Center For Research Resources1998–1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1997–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1999
  • Oral Prednisone In HIV Infection With Unexplained Weight LossNational Center For Research Resources1996–1997
  • Antiviral Activity Of GEM 91 In HIV Positive AdultsNational Center For Research Resources1996
  • Itraconazole And Fluconazole In Relapse Of Aids-Related Cryptococcal MeningitisNational Center For Research Resources1995
  • AMP B/Flucytosin VS AMP B/Fluconazole In Acute Cryptococcal MeningitisNational Center For Research Resources1995
  • AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
  • Recombinant Cd4-Immunoglobulin In HIV Infection And Sensitivity To Rcd4-IggNational Center For Research Resources1993–1995
  • Trimetrexate W/Leucovorin CA Rescue VS Pentamidine In AIDSNational Center For Research Resources1992–1995
  • SCH 39304 To Patients With Advanced HIV InfectionNational Center For Research Resources1992–1995
  • Randomized Double-Blind Protocol In Acute Crytococcal MeningitisNational Center For Research Resources1992–1995
  • L-697,661 Compared To AZT In HIV Sero-Positive PatientsNational Center For Research Resources1992–1995
  • Pharmacokinetics In HIV Infected AdultsNational Center For Research Resources1993
  • SCH 39304 For Acute Cryptococal Meningitis In HIV Infected PatientsNational Center For Research Resources1992–1993
  • Trimetrexate W/Leucovorin CA Rescue VS Trimethoprim/SulfamethoxazoleNational Center For Research Resources1990
  • Trimetrexate VS IV Pentamidine In AIDS Patients With PCP Refractory To T/SNational Center For Research Resources1990
  • Pharmacokinetic Study Of Single 600mg Oral Dose Of Sch39304National Center For Research Resources1990
  • Maintenance Fluconazole And Amphotericin B For Crypto Meningitis In AIDSNational Center For Research Resources1990

Hospital Affiliations